News

Nasdaq15d
Tempus to Report First Quarter 2025 Financial Results on May 6
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal ...
Crain's Chicago Business7d
Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.
The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...
Business Wire4d
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker ...
Yahoo Finance7d
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon.It's understandable if you identify with this. After ...
Business Wire8d
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand ...
01Net11d
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ...